Optimal vaccination program for healthy adults in China

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 10, 2015, Pages 2389-2394

  Yao, Jun ^a   Qiu, Yan ^b   Chen, Yongdi ^a   Jiang, Zhenggang ^a   Shen, Lingzhi ^a   Shan, Huan ^c   Dai, Xuewei ^d   Li, Qian ^a   Liu, Ying ^b   Ren, Wen ^b   Ren, Jingjing ^b  

^a ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d Jingdezhen Center for Disease Control and Prevention   (China)

Author keywords

Adult vaccination; Anti HBs titers; Hepatitis B vaccine; Immunogenicity

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS B ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CHINA; DRUG RESPONSE; FEMALE; GEOMETRIC MEAN TITER; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNOGENICITY; MALE; NORMAL HUMAN; SEROCONVERSION; SEROPROTECTION RATE; VACCINATION; ADOLESCENT; BLOOD; CONTROLLED STUDY; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; CHINA; FEMALE; HEALTHY VOLUNTEERS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84953924356     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1053674     Document Type: Article

References (25)

1. World Health Organization. Available from: URL: http://www.who.int/biologicals/vaccines/Hepatitis_B/en/
2. Li X, Zheng Y, Liau A, Cai B, Ye D, Huang F, Sheng X, Ge F, Xuan L, Li S, et al. Hepatitis B virus infections and risk factors among the general population in Anhui Province, China: an epidemio- logical study. BMC Public Health 2012; 12:272; PMID:22475135; http://dx.doi.org/10.1186/1471-2458-12-272
3. Zhu L, Zhai X, Zhu Y, Xu W, Bao C, Peng H, Bian Q, Yang H, Wang H, Hu Z. Evaluation of the Impact of Hepatitis B Vaccination in Adults in Jiangsu Province, China. PLoS One 2014; 9(6):e101501; PMID:24979048; http://dx.doi.org/10.1371/journal.pone.0101501
4. Ministry of Health of the People’s Republic of China. 2010 Health statistical yearbook of China. Beijing: Ministry of Health, China; 2011
5. Centers for Disease Control and Prevention (CDC). Progress in hepatitis B prevention through universal infant vaccination—China, 1997-2006. MMWR Morb Mortal Wkly Rep 2007; 56:441-5; PMID:17495790
6. Maynard JE, Kane MA, Alter MJ, et al. Control of hepatitis B by immunization: global perspectives. In: Viral hepatitis and liver disease. Vyas GN, Dienstag JL, Hoofnagle JH, ed. New York: Grune & Stratton; 1988:967-9.
7. Andre FE. Overview of a 5-year clinical experience with a yeast derived hepatitis B vaccine. Vaccine 1990; 8 (Suppl):S74-8; PMID:2139288; http://dx.doi.org/10.1016/0264-410X(90)90222-8
8. Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 1989; 7:106-10; PMID:2526419; http://dx.doi.org/10.1016/0264-410X(89)90046-7
9. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160:766-9; PMID:2530289; http://dx.doi.org/10.1093/infdis/160.5.766
10. Girisha KM, Kamat JR, Nataraj G. Immunological response to two hepatitis B vaccines administered in two different schedules. Indian J Pediatr 2006; 73:489-2394 91; PMID:16816509; http://dx.doi.org/10.1007/ BF02759892
11. Agladioglu S, Beyazova U, Camurdan AD, Sahin F, Atak A. Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules. Infection 2010; 38(4):269-73; PMID:20512395; http://dx.doi.org/10.1007/s15010-010-0031-2
12. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM Jr, Janssen RS, Ward JW; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:33; PMID:17159833
13. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981;1:377-85; PMID:7030902; http://dx.doi.org/10.1002/hep.1840010502
14. Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 1989 Apr; 7(2):106-10; PMID:2526419; http://dx.doi.org/10.1016/0264-410X(89)90046-7
15. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41; PMID:15738452; http://dx.doi.org/10.7326/0003-4819-142-5-200503-010-00008
16. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-6; PMID:19785526; http://dx.doi.org/10.1086/606119
17. Fisman DN, Agrawal D, Leder K. The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta-analysis. Clin Infect Dis 2002; 35:1368-75; PMID:12439800; http://dx.doi.org/10.1086/344271
18. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA1985; 254:3187-489; PMID:2933532
19. Shaw FE Jr, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, Roehm RR Jr, Talley WS, Hadler SC. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425-30; PMID:2530717; http://dx.doi.org/10.1016/0264-410X(89)90157-6
20. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15:8; PMID:9651632; http://dx.doi.org/10.1016/S0749-3797(98)00003-8
21. Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, Moore C, Pollard AJ, Rayco-Solon P, Sirugo G, van der Sande MA, et al. Host Genetic Factors and Vaccine-Induced Immunity to Hepatitis B Virus Infection. PLoS One 2008; 3:10; PMID:18365030
22. DeRave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994; 12:532-4; PMID:8036828; http://dx.doi.org/10.1016/0264-410X(94)90313-1
23. Estevez ZC, Betancourt AA, Gonzalez VM, Baile NF, Silva CV, Bernal FH, Arias EP, Delhanty Fernandez A, Olazabal NM, del Rıo Martın A, et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals 2007; 35:115-22; PMID:17056272; http://dx.doi.org/10.1016/j.biologicals.2006.06.001
24. Yuan YB, Wang ZQ, Ma XP, Zhang GH. Comparison of the immunogenicity of different dosages of recombinant yeast-derived hepatitis B vaccines in adults. J Prev Med Chin PLA 2003; 21(3):176-9. [In Chinese]
25. Ren JJ, Dai XW, Jiang ZG, Shen LZ, Chen YD, Li Q, Ren W, Liu Y, Yao J, Li LJ. Immunological effects of a 10-mg dose of domestic hepatitis B vaccine in adults. J Zhejiang Univ Sci B 2012; 13(11):948-54; PMID:23125088; http://dx.doi.org/10.1631/jzus.B1200179